CLINICAL_TRIALS ClinicalTrials.gov record update

A Prospective Study to Evaluate the Safety of Concurrent Durvalumab (MEDI4736) With Chemoradiation Therapy（CRT）Followed by Durvalumab for Chinese Unresectable Stage III Non Small Cell Lung Cancer（NSCLC）

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04982549
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:04.373946+00:00
Published At: 2021-08-06T00:00:00+00:00
Record Updated At: 2021-08-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Unresectable Stage III NSCLC"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-08-06"
protocolSection.identificationModule.nctId: "NCT04982549"
protocolSection.identificationModule.officialTitle: "A Prospective Study to Evaluate the Safety of Concurrent Durvalumab (MEDI4736) With Chemoradiation Therapy\uff08CRT\uff09Followed by Durvalumab for Chinese Unresectable Stage III Non Small Cell Lung Cancer\uff08NSCLC\uff09"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.